{
  "docId": "019dd923-622c-750b-8b99-b43d907adb44",
  "docSlug": "3c210b1fcba7",
  "documentTitle": "Tempus AI, Inc. (TEM)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-05-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 60,
  "pageCount": 76,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 16,
  "notes": "The slide uses a yellow highlight for Ambry to visually distinguish it as the subject of the critique.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "bar_chart_vertical",
    "kpi_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-b43d907adb44/60",
  "deckHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44#slide-60",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Ambry Genetics may be taking advantage of the lack of transparency and oversight surrounding CPT 81479 billing practices.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-fb91-749f-a6b2-009703b178b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.43
      },
      "kind": "chart",
      "text": "Medicare CPT 81479 Annual Revenues For Ambry, Myriad, Invitae, and Caris ($m)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ed77938-799d-4f0b-ace3-1ada9c24de8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.26,
        "y": 0.92
      },
      "kind": "metric",
      "text": "3-year CAGR: -3%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ededa27-cb5c-46bd-a09b-bb5988701ea4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.51,
        "y": 0.92
      },
      "kind": "metric",
      "text": "3-year CAGR: 24%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c8e68a3-88fa-4198-a572-14ef12b64bb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.75,
        "y": 0.92
      },
      "kind": "metric",
      "text": "3-year CAGR: 28%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e081b85-92bb-4c84-9288-56545ac695f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "metric",
      "text": "3-year CAGR: 78%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e9e6dcc-1889-425c-8754-d196683206fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.96,
        "x": 0.02,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Ambry Genetics may be taking advantage of the lack of transparency and oversight surrounding CPT 81479 billing practices. While other major genetic testing companies such as Myriad, Invitae, and Caris in aggregate saw growth in Medicare revenue from this unlisted, catchall code, Ambry's revenue exploded from $5.1 million in 2019 to $28.9 million in 2022—a staggering 78% compounded annual growth rate. Given that CPT 81479 is widely recognized as an opaque code often used when no specific billing code exists, Ambry's outlier status raises concerns that the company is capitalizing on the ambiguity of the code to maximize reimbursement in ways that may not be possible with more transparent, well-defined codes. This pattern stands out in an industry already grappling with inconsistent coding, unclear pricing, and payer confusion, suggesting that Ambry's billing practices under CPT 81479 deserve closer scrutiny.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b416650-1679-4587-b81e-1bb591a123bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.08,
        "x": 0.02,
        "y": 0.98
      },
      "kind": "source-note",
      "text": "Source: CMS.gov",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bd9a1fc-d941-4e73-ae3a-31d581ea0cfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.33,
        "y": 0.02
      },
      "kind": "title",
      "text": "Ambry's Outlier Growth in CPT 81479 Medicare Revenue",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3cecf34-0efb-4cfd-8394-3f6cf221eefb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "f43e979c-2f45-4569-86b8-afbe551f1c26",
      "evidence": "The slide features a comparison of growth rates between Ambry Genetics and other companies, potentially forming a 2x2 matrix.",
      "confidence": 0.5
    },
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019de87d-fe59-7381-9994-9ca7d8f395c2",
      "evidence": "Title labels Ambry 'Outlier Growth'",
      "confidence": 92
    },
    {
      "name": "Small Multiples",
      "slug": "small-multiples",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019de87d-fe7e-74d2-92cc-46ce13034d2d",
      "evidence": "Four parallel bar charts of CPT 81479 by company",
      "confidence": 92
    },
    {
      "name": "Von Restorff Effect",
      "slug": "von-restorff-effect",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019de87d-fea6-72e2-a2bb-ecc261c4ce8a",
      "evidence": "Ambry 78% CAGR box stands out vs others",
      "confidence": 85
    }
  ],
  "frameworks": [
    {
      "name": "Peer Gap Chart",
      "slug": null,
      "matchId": "019de87e-09a8-7449-8e09-82eb276aa42b",
      "evidence": "Four small-multiple bar charts comparing CAGR by peer",
      "confidence": 92
    }
  ],
  "arcBeats": [
    {
      "to": 69,
      "from": 12,
      "beatId": "019de87d-e40d-7574-b4dc-522b102a6735",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": null,
      "evidence": "Five evidence sections: insiders, AI hype, partnerships, accounting, billing.",
      "position": 4,
      "confidence": 78,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 69,
      "from": 12,
      "beatId": "019de87d-e501-7638-91f7-175bec763c5d",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": null,
      "evidence": "Mounting evidence across insiders, AI, partnerships, accounting, billing.",
      "position": 2,
      "confidence": 55,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 66,
      "from": 57,
      "name": "Benchmark Gap",
      "slug": "39-benchmark-gap",
      "bestFor": "Performance improvement, competitive analysis, target setting",
      "matchId": "019de87d-e6ef-77cf-9281-b1f3dc9c1d8c",
      "evidence": "Ambry 78% CAGR vs Myriad -3%, Invitae 24%, Caris 28% — explicit peer-gap chart with CAGR boxes.",
      "position": 7,
      "objective": "Show Ambry as outlier vs peers on CPT 81479 billing",
      "structure": "Our Performance -> Industry Average -> Best-in-Class -> The Gap = The Opportunity",
      "confidence": 87,
      "description": "Compare performance against best-in-class to quantify the opportunity"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}